Press Releases

Press Releases

Haoma Medica Limited is pleased to announce that the UKIPO office has granted two UK patent applications to Haoma Medica Limited, GB2476643 and GB2476644. Haoma Medica Limited is also pleased to announce the granting of patents in the US, Europe, China, Hong Kong, Japan, Australia, Israel and Russian. The equivalent protection is also being actively sought in a number of other countries, including Brazil, India, Canada and Korea.

Haoma Medica Limited focuses on treatments for Osteoporosis and Osteopenia as well as blood clotting management. The Osteoporosis & Osteopenia drug referred to as NaQuinate and commercially as Osteopura, is a novel class of compound, designed for low dose oral administration. Being a natural product, that preserves both bone mass and bone architecture, the safety profile of the therapeutic approach has significant potential for the long-term treatment of the serious problem of osteoporosis. The therapeutics in Osteopura are present in all people, but only in very, very small amounts, Osteopura boosts the levels of these agents to preserve bone integrity. Haoma Medica Limited started with the platform of "working with nature and not against it".